Inflammation-Induced CNS Glutamate During Breast Cancer Treatment
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - 65 |
| Updated: | 2/9/2019 |
| Start Date: | May 2015 |
| End Date: | June 2019 |
The purpose of this study is to try and provide data linking the impact of increased
inflammatory cytokines as a result of chemotherapy and their relationship with increased
levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer
patients. The investigators will use neuropsychiatric assessments, blood sampling and
Magnetic Resonance Spectroscopy (MRS) to collect study data.
inflammatory cytokines as a result of chemotherapy and their relationship with increased
levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer
patients. The investigators will use neuropsychiatric assessments, blood sampling and
Magnetic Resonance Spectroscopy (MRS) to collect study data.
Approximately 70% of women with breast cancer experience behavioral and/or cognitive symptoms
during treatment with chemotherapy and approximately 30% of women continue to experience
these symptoms months to years after treatment completion. There is mounting data to suggest
that inflammation may be involved and indicate that chemotherapy-treated breast cancer
patients exhibit higher inflammatory markers than non-chemotherapy-treated patients, and
inflammatory markers including interleukin (IL)-6 and soluble tumor necrosis factor (sTNFR2)
have been associated with chemotherapy-induced depression and fatigue.
during treatment with chemotherapy and approximately 30% of women continue to experience
these symptoms months to years after treatment completion. There is mounting data to suggest
that inflammation may be involved and indicate that chemotherapy-treated breast cancer
patients exhibit higher inflammatory markers than non-chemotherapy-treated patients, and
inflammatory markers including interleukin (IL)-6 and soluble tumor necrosis factor (sTNFR2)
have been associated with chemotherapy-induced depression and fatigue.
Inclusion Criteria:
- Female breast cancer patients will have undergone surgery (lumpectomy or mastectomy)
with or without neoadjuvant or adjuvant chemotherapy
- Age between 21-65 years
Exclusion Criteria:
- Taking trastuzumab
We found this trial at
1
site
Atlanta, Georgia 30322
Principal Investigator: Andrew H. Miller, MD
Phone: 404-727-8229
Click here to add this to my saved trials
